Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP0274 in advanced HER2-positive solid tumors
NCT03084926Phase 1Completed
- Sponsor
- Molecular Partners AG
- Start
- Aug 2017
- Primary completion
- Dec 2021
- Modality
- Carrier/Scaffold Proteins
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of MP0274 in HER2-positive solid tumor, sponsored by Molecular Partners AG. Primary endpoint: Incidence and severity of adverse events up to 12 months. Started Aug 2017; status: completed.
02
Drugs
MP0274
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT03084926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084926.